JP2013536209A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536209A5
JP2013536209A5 JP2013525178A JP2013525178A JP2013536209A5 JP 2013536209 A5 JP2013536209 A5 JP 2013536209A5 JP 2013525178 A JP2013525178 A JP 2013525178A JP 2013525178 A JP2013525178 A JP 2013525178A JP 2013536209 A5 JP2013536209 A5 JP 2013536209A5
Authority
JP
Japan
Prior art keywords
spinal cord
injury
syndrome
stereoisomer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013525178A
Other languages
English (en)
Other versions
JP2013536209A (ja
JP5820476B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/004218 external-priority patent/WO2012025217A1/en
Publication of JP2013536209A publication Critical patent/JP2013536209A/ja
Publication of JP2013536209A5 publication Critical patent/JP2013536209A5/ja
Application granted granted Critical
Publication of JP5820476B2 publication Critical patent/JP5820476B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (8)

  1. 中枢神経系外傷関連障害の治療において使用するための、化学式(II)
    の化合物、または、その薬学的に許容可能な塩、溶媒和物、立体異性体もしくは誘導体であって、
    前記誘導体は、化学式(III)
    の化合物、または、その薬学的に許容可能な塩、溶媒和物もしくは立体異性体である、
    中枢神経系外傷関連障害の治療において使用するための化合物、または、その薬学的に許容可能な塩、溶媒和物、立体異性体もしくは誘導体。
  2. 前記化合物の前記立体異性体は、RまたはS鏡像異性体である、
    請求項1に記載の化合物、または、その薬学的に許容可能な塩、溶媒和物、立体異性体もしくは誘導体
  3. 前記中枢神経系外傷関連障害は、完全脊髄損傷、不完全脊髄損傷、脊髄挫傷、脊髄圧迫、脊髄外傷、脊髄損傷、対麻痺、四肢麻痺(quadriplegia)、四肢麻痺(tetraplegia)、脊髄中心部症候群、ブラウン・セカール症候群、脊髄前部症候群、脊髄円錐症候群、馬尾症候群、外傷性脳損傷、TBI、脳損傷、脳ダメージ、頭部外傷、びまん性軸索損傷(DAI)、頭部外傷、脳振盪、脳挫傷、硬膜下血腫、硬膜外血腫、クモ膜下出血、脳内出血、またはCNS圧迫である、
    請求項1又は2に記載の化合物、または、その薬学的に許容可能な塩、溶媒和物、立体異性体もしくは誘導体
  4. 前記中枢神経系外傷関連障害は、脊髄損傷または脊髄挫傷である、
    請求項1又は2に記載の化合物、または、その薬学的に許容可能な塩、溶媒和物、立体異性体もしくは誘導体
  5. 中枢神経系外傷関連障害を予防および/または治療するための医薬組成物であって、
    治療有効量の請求項1〜4のいずれか1項に記載の化合物、または、その薬学的に許容可能な塩、溶媒和物、立体異性体もしくは誘導体を薬学的な許容可能な媒介物または賦形剤と混合して含む医薬組成物。
  6. 前記中枢神経系外傷関連障害は、完全脊髄損傷、不完全脊髄損傷、脊髄挫傷、脊髄圧迫、脊髄外傷、脊髄損傷、対麻痺、四肢麻痺(quadriplegia)、四肢麻痺(tetraplegia)、脊髄中心部症候群、ブラウン・セカール症候群、脊髄前部症候群、脊髄円錐症候群、馬尾症候群、外傷性脳損傷、TBI、脳損傷、脳ダメージ、頭部外傷、びまん性軸索損傷(DAI)、頭部外傷、脳振盪、脳挫傷、硬膜下血腫、硬膜外血腫、クモ膜下出血、脳内出血、またはCNS圧迫である、
    請求項に記載の医薬組成物。
  7. 前記中枢神経系外傷関連障害は、脊髄損傷または脊髄挫傷である、
    請求項に記載の医薬組成物。
  8. 脊髄損傷または脊髄挫傷を予防および/または治療するための医薬組成物であって、
    治療有効量のレフルノミドを薬学的な許容可能な媒介物または賦形剤と混合して含み、第2活性薬剤としての免疫調節性化合物を含まない医薬組成物
JP2013525178A 2010-08-24 2011-08-23 レフルノミドおよびマロノニトリラマイドの新規の使用 Active JP5820476B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37645310P 2010-08-24 2010-08-24
US61/376,453 2010-08-24
EP10008802.0 2010-08-24
EP10008802 2010-08-24
PCT/EP2011/004218 WO2012025217A1 (en) 2010-08-24 2011-08-23 Novel use of leflunomide and malononitrilamides

Publications (3)

Publication Number Publication Date
JP2013536209A JP2013536209A (ja) 2013-09-19
JP2013536209A5 true JP2013536209A5 (ja) 2014-08-21
JP5820476B2 JP5820476B2 (ja) 2015-11-24

Family

ID=44587762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013525178A Active JP5820476B2 (ja) 2010-08-24 2011-08-23 レフルノミドおよびマロノニトリラマイドの新規の使用

Country Status (7)

Country Link
US (1) US8957098B2 (ja)
EP (1) EP2608782B1 (ja)
JP (1) JP5820476B2 (ja)
CN (1) CN103153295A (ja)
DK (1) DK2608782T3 (ja)
ES (1) ES2591355T3 (ja)
WO (1) WO2012025217A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034890T2 (hu) * 2010-10-29 2018-03-28 Algiax Pharmaceuticals Gmbh Malononitrilaminok alkalmazása neuropathiás fájdalomban
EP3928772A1 (en) * 2020-06-26 2021-12-29 Algiax Pharmaceuticals GmbH Nanoparticulate composition

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5494911A (en) 1990-05-18 1996-02-27 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0607775B1 (de) 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
DK2282778T3 (en) * 2008-04-29 2017-05-01 Pharnext NEW THERAPEUTIC APPROACHES TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES THROUGH A MODULATION OF ANGIOGENIC
EP2314291A1 (en) * 2009-10-22 2011-04-27 Sanofi-Aventis Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis

Similar Documents

Publication Publication Date Title
CO2018000858A2 (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il carbamato como inhibidores de magl
JP2017513864A5 (ja)
HRP20200836T1 (hr) Liječenje bolesti povezanih s imunitetom i upalnih bolesti
JP2009510044A5 (ja)
TN2018000121A1 (en) Valbenazine salts and polymorphs thereof
JP2015500223A5 (ja)
RU2019121667A (ru) Аминопиразолы в качестве селективных ингибиторов янус-киназы
JP2014506907A5 (ja)
BR112014029016A2 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
JP2012523395A5 (ja)
JP2021105002A5 (ja)
WO2014120808A8 (en) Pyridone amides as modulators of sodium channels
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
EP2279727A3 (en) Nanoparticulate aripiprazole formulations
WO2014078575A3 (en) Novel orally bioavailable breathing control modulating compounds, and methods of using same
PE20211600A1 (es) 2,3,5-trimetil-6-nonilclohexa-2,5-diena-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos
WO2012040258A3 (en) Therapeutic piperazines
RU2016131875A (ru) Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы
JP2016537338A5 (ja)
JP2020534270A5 (ja)
RU2015144483A (ru) N-(2-цианогетероциклил)пиразолопиридоны в качестве ингибиторов янус-киназы
WO2010018996A3 (ko) 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
BR112014029478A2 (pt) profármaco de aminoácido contendo flúor
JP2013536209A5 (ja)
JP2016515550A5 (ja)